

Supplementary Table 3 Reported incidence of severe hypoglycaemia worldwide.

Region/country	Method of hypoglycaemia reporting	Population	Incidence of hypoglycaemia	Study/reference
Spain	Events requiring emergency assistance	General	95.0±61.6 cases per 100,000 inhabitants	PAUEPAD project (present analysis)
Spain	Events requiring emergency assistance	Diabetes	0.008 per patient-year	PAUEPAD project ¹
Global	Questionnaire and patient diary	Type 2	2.5 per patient-year	HAT global ²
Northern Europe /Canada		diabetes	1.3 per patient-year	
Eastern Europe			2.2 per patient-year	
Latin America			3.7 per patient-year	
Middle East			2.4 per patient-year	
Russia			2.3 per patient-year	
Southeast Asia			3.4 per patient-year	
Austria, Czech Republic, Denmark, Finland, Germany, Ireland, Israel, The Netherlands, Sweden, Turkey, UK		Patient records, recall and patient diaries	Type 2 diabetes	
UK	Self-reporting and continuous glucose monitoring	Type 2 diabetes	<2 years: 0.1 per patient-year >5 years: 0.7 per patient-year	UK hypoglycaemia study ⁴
China, South Asia, East Asia, North Africa, Middle East/Gulf, Latin America, Russia	Patient records, recall, patient diaries and laboratory measurements	Type 2 diabetes	Naïve: 0.0 per patient-year Experienced: 0.01 per patient-year	A(1)chieve study ⁵
India	Data collection forms (recall)	Type 2 diabetes	0.05 per patient-year	PRESENT study ⁶

Region/country	Method of hypoglycaemia reporting	Population	Incidence of hypoglycaemia	Study/reference
USA	Emergency department or inpatient medical encounters extracted from the clinical database of health care system	Adults with diabetes	0.015 per patient-year	SUPREME-DM study ⁷

References

1. Barranco RJ, Gomez-Peralta F, Abreu C, *et al.* Incidence and care-related costs of severe hypoglycaemia requiring emergency treatment in Andalusia (Spain): the PAUEPAD project. *Diabet Med* 2015;32(11):1520-6. doi: 10.1111/dme.12843
2. Khunti K, Alsifri S, Aronson R, *et al.* Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. *Diabetes Obes Metab* 2016;18(9):907-15. doi: 10.1111/dom.12689
3. Dornhorst A, Luddeke HJ, Sreenan S, *et al.* Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. *Int J Clin Pract* 2007;61(3):523-8. doi: 10.1111/j.1742-1241.2007.01316.x
4. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. *Diabetologia* 2007;50(6):1140-7. doi: 10.1007/s00125-007-0599-y
5. Zilov A, El Naggar N, Shah S, *et al.* Insulin detemir in the management of type 2 diabetes in non-Western countries: safety and effectiveness data from the A(1)chieve observational study. *Diabetes Res Clin Pract* 2013;101(3):317-25. doi: 10.1016/j.diabres.2013.06.003
6. Sharma SK, Joshi SR, Kumar A, *et al.* Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study. *J Assoc Physicians India* 2008;56:859-63.
7. Pathak RD, Schroeder EB, Seaquist ER, *et al.* Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005-2011. *Diabetes Care* 2016;39(3):363-70. doi: 10.2337/dc15-0858